logo-loader
RNS
Shield Therapeutics PLC

Director/PDMR Shareholding

/**/ link{ color: blue }visited{ color: #954F72 } .bb{size:595.3pt 841.9pt;margin:2.0cm 42.55pt 2.0cm 42.55pt;}div.bb{}p.cl{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin: 0cm; margin-bottom: .0001pt; text-align: center}span.cm{color: black; font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}p.cn{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin: 0cm; margin-bottom: .0001pt; text-align: center}span.co{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}p.cp{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify}p.cq{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify}span.cr{color: black; font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}span.cs{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black} span.ce{font-size:11.0pt; font-family:"Calibri","sans-serif";color:black}span.j{}span.cf{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}p.ct{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin: 0cm; margin-bottom: .0001pt; text-align: center}span.ch{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}table.cu{width:525.4pt;margin-left:-13.0pt;border-collapse:collapse}td.cb{border:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt}p.cv{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: justify}td.ca{border:solid windowtext 1.0pt;border-left: none;padding:0cm 5.4pt 0cm 5.4pt}td.by{border:solid windowtext 1.0pt;border-top:none; padding:0cm 5.4pt 0cm 5.4pt} p.cw{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal}td.bx{border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt; border-right:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt}td.bw{border-top:none;border-left:none;border-bottom: solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt}p.cx{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:18.0pt;margin-bottom:.0001pt;text-indent:-18.0pt;line-height: normal}span.bv{font-family:Symbol}span.bs{font-family:"Times New Roman","serif"; color:black}span.br{color:black}table.cy{width:496.15pt;margin-left:-5.4pt;border-collapse:collapse}td.bp{width:220.2pt;padding:0cm 5.4pt 0cm 5.4pt}p.cz{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm} td.bn{width:254.35pt;padding:0cm 5.4pt 0cm 5.4pt}p.da{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: normal; margin-bottom: 0cm; text-align: right}p.db{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;line-height: normal}p.dc{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; font-weight: bold; line-height: normal; margin-bottom: 0cm}span.bk{background:white}p.dd{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt; text-align:justify;line-height:normal}p.de{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt; text-align:justify;line-height:normal}p.df{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin: 0cm; margin-bottom: .0001pt; text-align: justify}p.dg{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify}span.dh{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black} span.bg{font-size:11.0pt;font-family:"Calibri","sans-serif"}span.bf{font-size:13.5pt;color:black}p.di{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify}span.dj{color: black; font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-div: italic; font-weight: bold}p.dk{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify}span.dl{color: black; font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-div: italic}p.a,li.a,div.a{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";}span.bc{font-size:13.5pt;line-height:107%;color:black} /**/
RNS Number : 1839J
Shield Therapeutics PLC
15 August 2019
 

 

Shield Therapeutics plc

("Shield" or the "Company")

 

Director / PDMR Shareholding

 

London, UK, 15 August 2019, Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company with an initial focus on addressing iron deficiency, announces that James Karis, Chairman of the Company, has acquired 75,000 Ordinary Shares in the Company on 13 August 2019 for consideration of £1.78 per Ordinary Share. Following the transaction, Mr Karis holds 161,667 shares, representing 0.001% of the Company's issued share capital.

 

The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

Details of the person discharging managerial responsibilities/person closely associated

 

a)

Name

 

James Karis                       

 

2

Reason for the notification

 

a)

Position/status

 

Chairman

b)

Initial notification/ Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name

 

Shield Therapeutics plc

b)

LEI

 

213800G74QWY15FC3W71

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

 

 

 

 

 

 

 

Description of the financial instrument, type of instrument

 

 

 

Identification code

 

Ordinary shares of 1.5p each in the capital of the Company

 

 

 

ISIN of Ordinary Shares: GB00BYV81293

b)

 

 

Nature of the transaction

 

 

 

Acquisition of Ordinary Shares

c)

Price(s) and volume(s)

 

£1.78 per Ordinary Share

Volumes: 75,000

 

 

d)

Aggregated information

 

-Aggregated volume

 

-Price

 

 

 

75,000

 

£133,500

e)

Date of the transaction

 

13 August 2019

 

f)

Place of the transaction

 

London Stock Exchange, AIM Market

  

For further information please contact:

 

Shield Therapeutics plc

www.shieldtherapeutics.com

Carl Sterritt, Chief Executive Officer

+44 (0)20 7186 8500

Tim Watts, Chief Financial Officer




Nominated Adviser and Joint Broker


Peel Hunt LLP


James Steel/Dr Christopher Golden

+44 (0)20 7418 8900

 

 


Joint Broker


finnCap Ltd

+44 (0)20 7220 0500

Geoff Nash /Matt Radley/ Alice Lane                                    

 

 



Financial PR & IR Advisor


Walbrook PR

+44 (0)20 7933 8780 or [email protected]

Paul McManus / Lianne Cawthorne

+44 (0)7980 541 893 / +44 (0)7584 391 303

 

 

About Shield Therapeutics plc

Shield is a de-risked, commercial stage, specialty pharmaceutical company delivering innovative pharmaceuticals to address patients' unmet medical needs.  The Company's clear purpose is to help its patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives.  The Group has a marketed product, Feraccru®/Accrufer®, for the treatment of iron deficiency in adults which has exclusive IP rights until the mid-2030s.  Feraccru®/Accrufer® is approved by the FDA, EMA and Swiss Medic for the treatment of iron deficiency in adults and is commercialised in the European Union by Norgine BV, with a US commercialisation partner currently being selected.  For more information please visit www.shieldtherapeutics.com.

 

Forward-Looking Statements

This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements.  These forward-looking statements are based on management's current expectations and include statements related to the commercial strategy for Feraccru®/Accrufer®.  These statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties, many of which are beyond our control, that may cause actual results, performance or achievements to be materially different from management's expectations expressed or implied by the forward-looking statements, including, but not limited to, risks associated with, the Group's business and results of operations, competition and other market factors.  The forward-looking statements made in this press release represent management's expectations as of the date of this press release, and except as required by law, the Group disclaims any obligation to update any forward-looking statements contained in this release, even if subsequent events cause our views to change.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHKELBFKVFFBBQ

Quick facts: Shield Therapeutics PLC

Price: £1.82

Market: LSE
Market Cap: £213.4 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Shield's Feraccru likely to command 'high market share and branded pricing'

Capital Network analyst Emma Ulker assesses recent progress made at Shield Therapeutics PLC (LON:STX) with its lead asset Feraccru. The drug's approved and marketed in Europe, with a US approval decision pending for July 27. Feraccru is an oral product absorbed in the gut. It's also...

on 05/10/2019